25 April 2024 - trading update
Strong first quarter results from pharmaceutical group AstraZeneca have resulted in the shares rising to over £120 compared with our tip at exactly £96 in the February issue of cityconfidential. Revenue for the first quarter rose by a very impressive 17% with core earnings per share up 7% to $2.06. These are clearly excellent results and the company has re-iterated its guidance for the full year including the fact that the full year dividend will be $3.10 per share. The shares may well test their all-time high of 12294p from February . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
